UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN C000000329
Receipt No. R000000374
Scientific Title A randomized controlled trial comparing renoprotective effect of conventional diuretics (furocemide and potassium canrenoate) with carperitide and conventional diuretics alone in liver transplant recipients.
Date of disclosure of the study information 2006/02/10
Last modified on 2015/08/08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A randomized controlled trial comparing renoprotective effect of conventional diuretics (furocemide and potassium canrenoate) with carperitide and conventional diuretics alone in liver transplant recipients.
Acronym A randomized controlled trial evaluating the renoprotective effect of carperitide in liver transplant recipients.
Scientific Title A randomized controlled trial comparing renoprotective effect of conventional diuretics (furocemide and potassium canrenoate) with carperitide and conventional diuretics alone in liver transplant recipients.
Scientific Title:Acronym A randomized controlled trial evaluating the renoprotective effect of carperitide in liver transplant recipients.
Region
Japan

Condition
Condition liver transplantation recipients
Classification by specialty
Hepato-biliary-pancreatic surgery
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To compare the renoprotective effect of conventional diuretics (furosemide and pottassium canrenoate) combined with carperitide (hANP), and conventional diuretics alone in patients with renal insufficiency after liver transplantation.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Pragmatic
Developmental phase Phase II

Assessment
Primary outcomes The number (rate) of cases requiring induction of hemo-dialysis due to insufficient diuresis fulfilling the following criteria.
1)Serum creatinine of >6.0mg/dl
2)Oliguria(1ml/kg/hr)lasting over 6hours
3)Serum potassium of > 6.0mEq/l
Key secondary outcomes 1)Body weight
2)Blood pressure, pulse rate, urine volume
3)Serum creatinine, urea nitrogen
4)Serum atrial natriuretic peptide, aldosterone, brain natriuretic peptide, cyclic GMP
5)Serum renin activity
6)Urine creatinine
7)Urine NAG
8)Urine L-FABP
9)creatinine clearance

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification YES
Dynamic allocation YES
Institution consideration Institution is not considered as adjustment factor.
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Intravenous administration of carperitide by the central dose of 0.1ug/kg/min, which is modulated between 0.025 and 0.22ug/kg/min according to the reactive urination.
Interventions/Control_2 Dose up of conventional diuretics(flosemide; up to 2mg/kg/day, pottassium canrenoate; up to 8mg/kg/day ) alone.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
18 years-old <=
Age-upper limit
65 years-old >=
Gender Male and Female
Key inclusion criteria Patient selection: Patients who present with the following findings despite the use of conventional diuretics (furocemide up to 0.4mg/kg/day and potassium canrenoate up to 4mg/kg/day) among those who fulfill the above conditions and agreed to participate; A.) Elevated serum creatinine more than oe equal to 1mg/dl compared to that of preoperative value. B.) Oliguria less than or equal to 1ml/kg/h within 3 days postoperatively (evaluated q6 hours).
Key exclusion criteria Exclusion criteria
1) Patients on chronic hemo-dialysis.
2) Patients who required hemo-dialysis prior to transplantation. (Includes the use of continuous hemo-diafiltration for treating hepatic coma in fulminant hepatic failure)
3) Patients with underlying complications such as diabetes, hypertension, heart disease, hepatopulmonary syndrome, pulmonary hypertension etc.
4) Patients with renal disease other than hepatorenal syndrome.
5) Patients with contraindicated conditions for the use of studied agent such as pheochromocytoma, epilepsy, and right ventricle infarction.
6) Those that are considered ineligible by the participating physician.
Target sample size 50

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yasuhiko Sugawara
Organization University of Tokyo
Division name Artificial Organ and Transplantation Division, Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery
Zip code
Address 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan 113-8655
TEL +81-3-3815-5411
Email yasusuga-tky@umin.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Yasuhiko Sugawara
Organization University of Tokyo
Division name Artificial Organ and Transplantation Division, Hepato-Biliary-Pancreatic Surgery Division, Departme
Zip code
Address 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan 113-8655
TEL 03-3815-5411
Homepage URL
Email yasusuga-tky@umin.ac.jp

Sponsor
Institute The Artificial Organ and Transplantation Division, Department of Surgery
Institute
Department

Funding Source
Organization The Artificial Organ and Transplantation Division, Department of Surgery
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2006 Year 02 Month 10 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2005 Year 01 Month 27 Day
Date of IRB
Anticipated trial start date
2005 Year 12 Month 01 Day
Last follow-up date
2011 Year 12 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2006 Year 02 Month 08 Day
Last modified on
2015 Year 08 Month 08 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000374

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.